Scientific Protein Profiling Service

Supporting the fight against COVID-19

Learn how Sciomics supports COVID-19 research

Accelerated research is the best opportunity to increase the understanding of COVID-19 disease and efficiently fighting the novel coronavirus SARS-CoV-2. Testing multiple proteins in parallel accelerates your research and enables in-depth insights regarding the underlying molecular mechanisms.

Learn here how multiplex protein profiling can support your COVID-19 research. All information is also available as a pdf.

Immune Response Profiling & Biomarker Discovery

> Immune Response Profiling

Explore how the immune system reacts to a SARS-CoV-2 infection in different age groups, risk groups and certain individuals. Are there common mechanisms which can be used for preventing severe disease ? A parallel profiling of 121 cytokines / chemokines and 141 cell surface markers can provide novel insights. Such analyses are possible from patient samples (plasma / serum), cell culture as well as animal models.

< scioCD > < scioDiscover >

> Disease Severity biomarkers for COVID-19

Discover new biomarkers for COVID-19 patient stratification, early prevention and improvement of disease management by multiplex screens from plasma or serum samples.
< scioDiscover >

> Outcome Prediction after positive SARS-CoV-2 test

Identify risk factors and correlating protein biomarkers indicating severe COVID-19 progression for improved disease management.
< scioDiscover >

Development of therapeutics against COVID-19

> Benchmarking of Therapeutics & Drug Repurposing

Accelerate your COVID-19 research by assessing pathway activity, early toxicology and mechanisms of action for an efficient benchmarking of compounds or drug repurposing candidates.
< scioDiscover > < scioPhospho >

> Therapy Response biomarkers

Identify predictive biomarkers for your COVID-19 drug candidate to stratify responders from non-responders
< scioDiscover >

Development of vaccines against SARS-CoV-2

> SARS-CoV-2 vaccine development

In-depth analysis of responses to vaccine candidates from animal and patient samples. Analyses are possible from plasma / serum samples or from purified immune cells.
< scioCD > < scioDiscover > < scioPhospho >

> Profiling of animal models

Characterize response in different model organisms (mouse, rat and more) for your SARS-CoV-2 vaccine development
< scioDiscover > < scioPhospho >

> Screening of viral SARS-CoV-2 epitopes

Analyse the antibody response to different vaccine candidates in animal models and patients using plasma/serum samples.
Analyse serum samples from COVID-19 patients to identify highly immunogenic epitopes.

Assays available

scioCD - 121 cytokines and 141 CD cell surface markers for immune profiling

Parallel profiling of 121 cytokines / chemokines and 141 CD cell surface markers from plasma/serum, immune cells or tissue samples.

< more information >

scioDiscover - screening of 1,300 proteins in parallel

The protein panel for biomarker discovery on plasma/serum, cell or tissue samples include

inflammatory mediators
immune checkpoint molecules
immune cells markers
soluble proteins
membrane/receptor proteins
intracellular proteins

< more information >

scioPhospho - combined phosphorylation and expression profiling of 1,300 proteins

Combine a scioDiscover screen with information on phosphorylation status for all 1,300 proteins in one assay. Typical applications are mode-of-action studies, pathway activity profiling or mechanistic understanding of disease as well as therapeutic response.
< more information >

Common assay specifications

Minimal sample amount required (20 µL plasma/serum, 500,000 cells, 10mg of tissue)
Complete analysis service from sample to study report
All assays can be complemented by a SARS-CoV-2 proteome wide peptide array < more information >